VTCN1 and neoplasm: By modulating various mechanisms involved in immune recognition and tumor survival, such as down-regulating PD-L1, PD-L2 and B7-H4, the application of HDAC6 inhibitors exhibited an anti-tumor effect, which might provide theoretical basis to apply HDAC6 inhibitors in cancer immunotherapy (42).